Remove 2028 Remove Dosage Remove Vaccines
article thumbnail

N-FIS was developed to address a critical challenge in healthcare—needle phobia

Express Pharma

Research has reported that fear of needles constitutes about 20-50 per cent among children and 20-30 per cent among adults globally; often leading to missed vaccinations and delayed treatments. How does the company collaborate with pharma and vaccine companies to optimise efficacy of medicines with this delivery system?

article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Subject to planning permission, the site is expected to be opened by 2028. The new £26.4